Oral Bioavailability and Disposition Characteristics of Irbesartan, an Angiotensin Antagonist, in Healthy Volunteers
Authors:
- Theodore J. ChandoTCTheodore J. Chando
- 1 August 1998
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 38 (8) , 702-707
Abstract
Absolute oral bioavailability and disposition characteristics of irbesartan, an angiotensin II receptor antagonist, were investigated in 18 healthy young male volunteers. Subjects received [14C] irbesartan as a 30‐minute intravenous infusion (50 mg), [14C] irbesartan orally as a solution (50 mg or 150 mg), or irbesartan capsule (50 mg). Irbesartan was rapidly and almost completely absorbed after oral administration, and exhibited a mean absolute oral bioavailability of 60% to 80%. Mean total body clearance was approximately 157 mL/min, and renal clearance was 3.0 mL/min. Volume of distribution at steady state was 53 L to 93 L, and terminal elimination half‐life was approximately 13 to 16 hours. Hepatic extraction ratio was low (0.2). There were no major circulating metabolites, and approximately 80% of total plasma radioactivity was attributable to unchanged irbesartan. Regardless of route of administration, approximately 20% of dose was recovered in urine and the remainder in feces.Keywords
This publication has 13 references indexed in Scilit:
- Pharmacokinetics and Pharmacodynamics of Irbesartan in Healthy SubjectsThe Journal of Clinical Pharmacology, 1998
- High-performance liquid chromatographic assay for the quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 1997
- Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral doseXenobiotica, 1997
- Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humansClinical Pharmacology & Therapeutics, 1995
- Effects of irbesartan (SR 47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of actionEuropean Journal of Pharmacology, 1995
- Hemodynamic and Biochemical Effects of the AT1Receptor Antagonist Irbesartan in HypertensionHypertension, 1995
- Effects of modulators of the renin???angiotensin???aldosterone system on coughJournal Of Hypertension, 1994
- Angiotensin II Receptor Blockade: An Innovative Approach to Cardiovascular PharmacotherapyThe Journal of Clinical Pharmacology, 1993
- Clinical Pharmacokinetics in Patients with Liver DiseaseClinical Pharmacokinetics, 1991
- The application of statistical moment theory to the evaluation ofin vivo dissolution time and absorption timeJournal of Pharmacokinetics and Biopharmaceutics, 1980